Lins L, Brasseur R, Malaisse W J
Centre de Biophysique Moléculaire Numérique, Faculté Universitaire de Gembloux, Gembloux, Belgium.
Biochem Pharmacol. 1995 Nov 27;50(11):1879-84. doi: 10.1016/s0006-2952(99)80003-3.
Non-sulfonylurea hypoglycemic agents of the meglitinide family such as S3075, repaglinide, KAD-1229, and A-4166, were found to display a comparable U-shaped conformation by molecular modelling, with hydrophobic cycles placed at the extremity of each branch and a peptidic bond placed at the bottom of the U. A comparable conformation was observed with the hypoglycemic sulfonylureas glibenclamide and glimepiride. A different conformation with a greater distance between the hydrophobic cycles at the extremity of each branch was found, however, with the biologically inactive enantiomers of A-4166 and repaglinide and the poorly efficient insulinotropic agent meglitinide. The identification of a common conformation of these hypoglycemic agents may help in the design of highly active compounds and provide an imprint of their postulated target receptor on the pancreatic B-cell plasma membrane.
发现米格列奈家族的非磺酰脲类降糖药,如S3075、瑞格列奈、KAD - 1229和A - 4166,通过分子建模显示出类似的U形构象,疏水环位于每个分支的末端,肽键位于U的底部。降糖磺酰脲类药物格列本脲和格列美脲也观察到类似的构象。然而,在A - 4166和瑞格列奈的无生物活性对映体以及低效促胰岛素剂米格列奈中,发现了一种不同的构象,每个分支末端的疏水环之间距离更大。确定这些降糖药的共同构象可能有助于设计高活性化合物,并提供它们假定的靶受体在胰腺β细胞膜上的印记。